Transthoracic echocardiographic findings in patients admitted with SARS-CoV-2 infection

Jason P. Schott DO1 | Amy N. Mertens DO1 | Richard Bloomingdale MD1 | Thomas F. O’Connell MD1 | Michael J. Gallagher MD1,2 | Simon Dixon MBChB1,2 | Amr E. Abbas MD1,2

1Department of Cardiovascular Medicine, Beaumont Hospital Royal Oak, Royal Oak, MI, USA
2Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA

Correspondence
Amr E. Abbas, Beaumont Hospital Royal Oak, Royal Oak, Michigan, USA.
Email: aabbas@beaumont.edu

Abstract

Introduction: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)–infected patients commonly have elevated troponin and D-dimer levels, but limited imaging exists to support most likely etiologies in efforts to avoid staff exposure. The purpose of this study was to report transthoracic echocardiographic (TTE) findings in SARS-CoV-2 patients with correlating troponin and D-dimer levels.

Methods: We identified 66 SARS-CoV-2 patients (mean age 60 ± 15.7 years) admitted within a large, eight-hospital healthcare system over a 6-week period with a TTE performed. TTE readers were blinded to laboratory data with intra-observer and inter-observer analysis assessed.

Results: Sixty-six of 1780 SARS-CoV-2 patients were included and represented a high-risk population as 38 (57.6%) were ICU-admitted, 47 (71.2%) had elevated D-dimer, 41 (62.1%) had elevated troponin, and 25 (37.9%) died. Right ventricular (RV) dilation was present in 49 (74.2%) patients. The incidence and average D-dimer elevation was similar between moderate/severe vs. mild/no RV dilation (69.6% vs 67.6%, P = 1.0; 3736 ± 2986 vs 4141 ± 3351 ng/mL, P = .679). Increased left ventricular (LV) wall thickness was present in 46 (69.7%) with similar incidence of elevated troponin and average troponin levels compared to normal wall thickness (66.7% vs 52.4%, P = .231; 0.88 ± 1.9 vs 1.36 ± 2.4 ng/mL, P = .772). LV dilation was rare (n = 6, 9.1%), as was newly reduced LV ejection fraction (n = 2, 3.0%).

Conclusion: TTE in SARS-CoV-2 patients is scarce, technically difficult, and reserved for high-risk patients. RV dilation is common in SARS-CoV-2 but does not correlate with elevated D-dimer levels. Increased LV wall thickness is common, while newly reduced LV ejection fraction is rare, and neither correlates with troponin levels.

KEYWORDS
D-Dimer, SARS-CoV-2, transthoracic echocardiography, troponin
1 | INTRODUCTION

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused an upheaval in healthcare delivery by limiting imaging, invasive therapies, and face-to-face encounters despite abnormal vital signs and laboratory data. Acute cardiac injury has been reported in 7%–28% of cases, largely defined by elevated troponin levels. Elevated D-dimer levels have been reported in up to 68% of cases with anecdotal reports of hypercoagulability. However, diagnostic abilities are hindered by limited testing to avoid personnel exposure and preserve personal protective equipment. Transthoracic echocardiography (TTE) is a readily available, high-yield modality that can aid in these cases, but literature for TTE in SARS-CoV-2 is scarce. The purpose of this correspondence was to describe TTE findings in patients with SARS-CoV-2. A secondary aim was to associate these TTE findings with D-dimer and troponin levels.

2 | METHODS

2.1 | Population

Patients were included (n = 66, mean age 60 ± 15.7 years) if admitted with SARS-CoV-2 and underwent a TTE within Beaumont Health’s eight-hospital system across three counties in southeast Michigan from March 2 to April 11, 2020. Patients were excluded if younger than 18 years old. The study was approved by the Institutional Review Board, and consent was waived.

2.2 | Echocardiography

Examinations were performed with dedicated full-capacity machines. Measurements were performed in accordance with the 2015 American Society of Echocardiography (ASE) quantification guidelines by two readers (JS and RB) blinded to each other and laboratory data. Inter-observer and intra-observer variations were analyzed with 25% of examinations over-read. Right ventricular (RV) enlargement was defined by the ratio of RV to left ventricular (LV) basal diameter classified as mild (0.67–0.9), moderate (1.0), and severe (>1.0) enlargement. RV dysfunction was assessed visually as Doppler evaluation was limited. LV dilation was determined by volumetric dimensions per ASE guidelines.

2.3 | Laboratory studies

Nucleic acid testing for SARS-CoV-2 was obtained during the index hospitalization via nasal swab or respiratory culture. Serum assays were also obtained during the index hospitalization. Elevated troponin I level was defined as >0.03 ng/mL, and elevated D-dimer level was defined as >499 ng/mL.

2.4 | Statistical analysis

Categorical variables were presented as number and percentages, while continuous variables were presented as averages with standard deviation. Median values were also provided for continuous echocardiographic variables. A t-test was used for assessment of average D-dimer levels between RV dimension groups, but otherwise, a Mann-Whitney U test was used to compare continuous variables. A Fisher exact test was used to compare categorical variables. Inter-observer and intra-observer variabilities were calculated by (A − B)/[(A + B)/2], with A representing the primary measurement and B representing the secondary measurement.

3 | RESULTS

3.1 | Population

Of 1780 patients admitted with SARS-CoV-2, 66 underwent a TTE. Patients were commonly African American, male, obese, with hypertension, and with diabetes (Table 1). Troponin and D-dimer levels were frequently elevated. D-dimer and troponin levels were not obtained in 16 and 7 patients, respectively. The majority were ICU-admitted (n = 38, 57.6%) with 23 (34.8%) mechanically ventilated (MV), and 25 (37.9%) died. TTE indications included shock, cardiopulmonary failure, and concern for new wall-motion abnormalities. Examinations were predominantly focused, and timing averaged 3 ± 4.5 days from admission.

3.2 | Right ventricle and D-dimer findings

RV dilation was common, but typically with intact systolic function (Table 2). RV size could not be graded in 6 patients with technically difficult studies due to poor acoustic windows, but function could be visually assessed in 5 of these patients using multiple alternative views. The incidence of elevated D-dimer was similar among those with moderate/severe vs. mild/no RV dilation (16[69.6%] vs 25[67.6%], P = 1.0). Average D-dimer levels in moderate/severe vs. mild/no RV dilation were 3736 ± 2986 vs 4141 ± 3351 ng/mL (P = .679). The mortality rate in patients with moderate/severe dilation was 50% vs. 26.3% among those with mild/no RV dilation (P = .09). The mortality was similar among patients with elevated and normal D-dimer (20 [40.4%] and 1 [33.3%], P = 1) irrespective of RV size. Pulmonary hypertension was confirmed in 3 and excluded in 19 patients. A small pericardial effusion was present in 7 (10.6%).

3.3 | Left ventricle and troponin findings

Most patients had increased LV wall thickness (WT) while dilation was rare (Table 3). Troponin was elevated among tested patients with and without increased WT in 30 (66.7%) and 11 (52.4%), respectively.
Our population represents a high-risk group evident by higher troponin levels (19 [46.3%] vs 3 [16.7%], P < .05) irrespective of LVEF. Elevated troponin portended a significantly higher mortality when compared to patients with normal troponin levels (19 [46.3%] vs 3 [16.7%], P < .05) irrespective of LVEF. (P = .231). Average troponin levels among those with vs. without increased WT were 0.88 ± 1.9 vs 1.36 ± 2.4 ng/mL (P = .772). Twelve patients had reduced ejection fraction (LVEF), seven had previously known, three without prior imaging, and two were newly diagnosed. Troponin was normal in patients with newly reduced LVEF, and no difference in average levels between preserved vs. low LVEF (0.96 ± 2 vs 1.8 ± 2.5 ng/mL, P = .11). Of those with elevated troponin, two patients were diagnosed with myocarditis and one with supraventricular tachycardia to explain the troponin elevation. Mortality rates were no different between those with low LVEF vs. normal LVEF (4 [33.3%] vs 21 [38.9%], P = 1). Elevated troponin portended a significantly higher mortality when compared to patients with normal troponin levels (19 [46.3%] vs 3 [16.7%], P < .05) irrespective of LVEF.

4 | DISCUSSION

Our population represents a high-risk group evident by higher D-dimer and troponin levels than previously reported, along with...
Not surprisingly, many had RV dilation (Figure 1),\(^9\) which could result from pulmonary embolism or elevated pulmonary vascular resistance from hypoxia and high mean airway pressures from extraordinary MV settings. There was no specific correlation with D-dimer levels and RV dilation. While average RV-focused dimensions were normal, 81.7% of patients had RV enlargement by RV:LV > 0.67. This is attributable to many patients with nondiagnostic/missing RV-focused views. To a lesser extent, the RV:LV may be impacted by decreased LV chamber sizes amidst a high inotropic state such as infection and sympathomimetic drug use. Interestingly, RV dilation was not associated with a higher mortality. Unlike previous reports,\(^1,3\) D-dimer elevation was also not associated with higher mortality. However, any conclusion is limited as only 3 patients in this study had a negative D-dimer measured.

Similarly, there was no correlation with reduced LVEF and elevated troponin. Very few had reduced LVEFs, of which most were previously reduced. This is consistent with a limited case series previously reported,\(^4\) and reports of nonobstructive coronaries amidst elevated troponin and ST elevation.\(^10\) The degree of troponin elevation trended toward higher average levels among patients with low LVEF, which is consistent with preexisting cardiac disease. While a low LVEF was not associated with a higher mortality, this study did re-demonstrate that elevated troponin is associated with a higher mortality rate.\(^2,3,11\) Patients with increased WT were more likely to have elevated troponin, but degree of elevation was higher with normal WT; albeit neither of these findings reached statistical significance. Without definitive testing and renal function correlates, we can only speculate patients with increased WT have higher likelihood of detectable troponin due to larger LV mass or confounding comorbidities, but higher levels in those with normal WT are associated with direct cell injury, strain, or underlying coronary artery disease.

The study limitations include technically difficult images due to MV, patient positioning, airspace disease, and obesity. As such, the mid-RV free wall was poorly visualized leading to the highest inter-observer and intra-observer variability of 0.36 and 0.27, respectively, when measuring RV wall thickness. The best inter-observer variability was 0–0.01 with tricuspid annular plane systolic excursion, RV pulsed Doppler S’, and right atrial pressure estimate. Intra-observer variability was best in assessing pericardial effusion, RV pulsed Doppler S’, and tricuspid regurgitation maximum velocity at 0–0.01. Selection bias occurred with our high-risk patient sample including severity of clinical status and baseline comorbidities. Attempts to limit testing also resulted in a low study sample size. Finally, confirmatory testing for abnormal findings is lacking to avoid staff exposure.

| TABLE 3 | Echocardiographic left ventricular findings in patients admitted with SARS-CoV-2 Infection |
|---------------------------------|---------------------------------|-------------------|-------------------|
| **Left ventricle dimension**     | **Mean ± SD**                   | **Median**        | **Normal Range**  |
| LV septal wall thickness (cm)    | 1.1 ± 0.25                      | 1.1               | 0.6–1.0           |
| LV posterior wall thickness (cm)| 1.1 ± 0.26                      | 1                 | 0.6–1.0           |
| LV ESV (mL)\(^1\)               | 34 ± 17                         | 32                | 21–61             |
| LV EDV (mL)\(^2\)               | 87 ± 24                         | 88                | 62–150            |
| Simpson’s Biplane LV EF (%)\(^2\)| 60 ± 12                         | 60                | 52–72             |
| Visual LV EF (%)                 | 59 ± 10                         | 60                | 52–72             |
| Increased LV wall thickness (n=62) |                                  |                   |                   |
| None                             | 16 (25.8)                       |                   |                   |
| Mild                             | 37 (59.7)                       |                   |                   |
| Moderate                         | 4 (6.4)                         |                   |                   |
| Severe                           | 5 (8.1)                         |                   |                   |
| LV Dilation (n=47)               |                                  |                   |                   |
| None                             | 40 (85.1)                       |                   |                   |
| Mild                             | 3 (6.4)                         |                   |                   |
| Moderate                         | 3 (6.4)                         |                   |                   |
| Severe                           | 1 (2.1)                         |                   |                   |

**Note:** Percent of non-diagnostic or missing measurements denoted: *<10, †10–19, ‡20–29, §30–39, ¶40–49, ¶§50–59, ¶¶70–79, ‡‡80–89.

EDV = End diastolic volume; EF = Ejection fraction; ESV = End systolic volume; LV = Left ventricle; SD = Standard Deviation.

**TABLE 3**

| **Left ventricle dimension** | **Mean ± SD** | **Median** | **Normal Range** |
|-----------------------------|---------------|------------|------------------|
| LV septal wall thickness (cm) | 1.1 ± 0.25    | 1.1        | 0.6–1.0          |
| LV posterior wall thickness (cm) | 1.1 ± 0.26 | 1          | 0.6–1.0          |
| LV ESV (mL)\(^1\)              | 34 ± 17       | 32         | 21–61            |
| LV EDV (mL)\(^2\)              | 87 ± 24       | 88         | 62–150           |
| Simpson’s Biplane LV EF (%)\(^2\)| 60 ± 12      | 60         | 52–72            |
| Visual LV EF (%)                | 59 ± 10       | 60         | 52–72            |
| Increased LV wall thickness     |               |            |                  |
| None                            | 16 (25.8)     |            |                  |
| Mild                            | 37 (59.7)     |            |                  |
| Moderate                        | 4 (6.4)       |            |                  |
| Severe                          | 5 (8.1)       |            |                  |
| LV Dilation (n=47)              |               |            |                  |
| None                            | 40 (85.1)     |            |                  |
| Mild                            | 3 (6.4)       |            |                  |
| Moderate                        | 3 (6.4)       |            |                  |
| Severe                          | 1 (2.1)       |            |                  |

**Note:** Percent of non-diagnostic or missing measurements denoted: *<10, †10–19, ‡20–29, §30–39, ¶40–49, ¶§50–59, ¶¶70–79, ‡‡80–89.

EDV = End diastolic volume; EF = Ejection fraction; ESV = End systolic volume; LV = Left ventricle; SD = Standard Deviation.
In conclusion, echocardiographic utilization with SARS-CoV-2 is minimal, clinically directed, and usually reveals significant RV dilatation in the face of elevated D-dimer. However, despite a troponin abnormality in over 60% of patients, LVEF is not commonly reduced but does coincide with increased WT.

**CONFLICTS OF INTEREST**

There are no conflicts of interest to disclose.
REFERENCES

1. Wang D, Hu BO, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
2. Guo T, Fan Y, Lu Z, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811.
3. Zhou F, Yu T, Cao B, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062.
4. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle Region - case series. N Engl J Med. 2020;382(21):2012-2022.
5. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.
6. Popović Z, Thomas J. Assessing observer variability: a user’s guide. Cardiovasc Diagn Ther. 2017;7(3):317-324.
7. Kirkpatrick JN, Mitchell C, Taub C, et al. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak. Am Coll Cardiol. 2020;75(24):3078-3084.
8. Andreini D, Arbelo E, Barbato E, et al. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
9. Guarracino F, Vetrugno L, Forfori F, et al. Lung, heart, vascular, and diaphragm ultrasound examination of COVID-19 patients: a comprehensive approach. J Cardiathorac Vasc Anesth. 2020. https://doi.org/10.1053/j.jvca.2020.06.013 [Epub ahead of print].
10. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19- a case series. N Engl J Med. 2020;382(25):2478-2480.
11. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802.

How to cite this article: Schott JP, Mertens AN, Bloomingdale R, et al. Transthoracic echocardiographic findings in patients admitted with SARS-CoV-2 infection. Echocardiography. 2020;37:1551-1556. https://doi.org/10.1111/echo.14835